Funding
InflaRx has announced the closing of its funding round, led by Affentranger Associates with bm-t (beteiligungsmanagement thuringen gmbh), enabling the Jena-based company to move its antibody for sepsis into clinical trials.
“Completing this large financing tranche in the middle of the current financial environment is a major achievement for our team. It reflects the strong commitment of our investors and the good development progress within the first year,” said founder Niels Riedemann. “We are now well financed to move our first project into clinical trials in the near future.”
Sepsis - also called blood poisoning - is the most frequent cause of death in non-cardiological intensive care units worldwide.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
